BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.

13 Wall Street analysts have issued 12-month price objectives for BioMarin Pharmaceutical's stock. Their BMRN share price forecasts range from $74.00 to $135.00. On average, they predict the company's share price to reach $113.67 in the next year. This suggests a possible upside of 7.7% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.

BioMarin Pharmaceutical's stock was trading at $88.35 at the beginning of 2022. Since then, BMRN stock has increased by 19.5% and is now trading at $105.56.
View the best growth stocks for 2022 here.

BioMarin Pharmaceutical saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 9,820,000 shares, a decline of 12.9% from the October 31st total of 11,270,000 shares. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is currently 7.7 days.
View BioMarin Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BMRN earnings forecast.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Wednesday, October, 26th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.12 by $0.04. The biotechnology company earned $505.30 million during the quarter, compared to analyst estimates of $516.03 million. BioMarin Pharmaceutical had a net margin of 4.18% and a trailing twelve-month return on equity of 2.50%. The company's quarterly revenue was up 23.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.03) EPS.

BioMarin Pharmaceutical issued an update on its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.12 billion.

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.50%), Vanguard Group Inc. (9.22%), Barclays PLC (1.21%), Palo Alto Investors LP (1.07%), California Public Employees Retirement System (0.71%) and UBS Asset Management Americas Inc. (0.69%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BMRN stock can currently be purchased for approximately $105.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $19.58 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.42 on an earnings per share basis.

The company employs 3,045 workers across the globe.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.